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Abstract  13 
Oligomers comprised of misfolded proteins are implicated as neurotoxins in the pathogenesis 14 
of protein misfolding conditions such as Parkinson's and Alzheimer's diseases. Structural, 15 
biophysical, and biochemical characterisation of these nanoscale protein assemblies is key to 16 
understanding their pathology and the design of therapeutic interventions, yet is challenging 17 
due to their heterogeneous, transient nature and low relative abundance in complex mixtures. 18 
Here, we demonstrate separation of heterogeneous populations of oligomeric α-synuclein, a 19 
protein central to the pathology of Parkinson's disease, in solution using microfluidic free-flow 20 
electrophoresis. We characterise nanoscale structural heterogeneity of transient oligomers on 21 
a timescale of seconds, at least two orders of magnitude faster than conventional techniques. 22 
Furthermore, we utilise our platform to analyse oligomer ζ-potential and probe the 23 
immunochemistry of wild-type α-synuclein oligomers. Our findings contribute to an improved 24 
characterisation of alpha-synuclein oligomers and demonstrate the application of microchip 25 
electrophoresis for the free-solution analysis of biological nanoparticle analytes. 26 
 27 
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Introduction  2 
Protein misfolding is a molecular hallmark of a number of increasingly prevalent human 3 
diseases.1 Amyloid fibrils formed from misfolded proteins are the major components of the 4 
Lewy bodies and senile plaques found in the brains of patients with neurodegenerative 5 
conditions such as Parkinson’s and Alzheimer’s diseases, respectively.2 However, fibrillar 6 
species possess low inherent toxicity themselves, and it is instead pre-fibrillar, oligomeric 7 
aggregates that are implicated as the principal cytotoxic agents in these disorders.3–5 The 8 
characterisation and quantitation of these protein nanoparticles in the context of their toxicity 9 
and aggregation propensity is therefore an area of intense interest.6,7 However, deciphering 10 
the structural attributes of oligomeric species, which exist as an intrinsically heterogenous 11 
population of structures during protein aggregation, is hard to achieve using established 12 
methods that report the properties of analyte mixtures in an ensemble-averaged manner. 13 
Although measurements of oligomer populations, taken throughout protein aggregation 14 
processes, have enabled coarse-grained relationships between structure and toxicity to be 15 
defined,8,9 they do not permit detailed characterisation of oligomer properties including ζ-16 
potential, which may also play a crucial role in determining oligomer aggregation propensity.10 17 
Furthermore, oligomers exist in a complex, dynamic milieu of protein–protein interactions, but 18 
current methodologies are often incapable of probing such systems on a timescale relevant to 19 
temporal changes in oligomer populations.11 Crucially, current methods for the separation of 20 
heterogeneous protein mixtures such as size exclusion chromatography (SEC), analytical 21 
ultracentrifugation (AUC) and native gel electrophoresis operate on timescales of minutes to 22 
hours, limiting temporal resolution. This feature is particularly important when analysing 23 
protein oligomers, since oligomer populations undergo continuous change throughout the 24 
aggregation process. In addition, existing techniques for oligomer analysis often perturb the 25 
system in question by dilution12 or use of non-solution state approaches,13,14 which may alter 26 
the oligomer properties that are observed due to dilution-driven dissociation or interaction with 27 
the surface.  28 
To address these challenges, we have developed an approach based upon multi-spectral 29 
microchip free-flow electrophoresis (μFFE) that achieves rapid solution-phase fractionation 30 
and in-situ analysis of heterogeneous mixtures of protein oligomers and monomers. Our 31 
approach enables second timescale separation and solution-phase analysis of oligomer 32 
mixtures, at least two orders of magnitude faster than conventional techniques. We focus on 33 
the aggregation and oligomerisation of alpha-synuclein (αS), a protein that is strongly 34 
implicated in the pathogenesis of Parkinson’s disease.15 Using this approach, complex 35 
oligomeric mixtures are fractionated on-chip to afford rapid oligomer quantification and 36 
characterisation of ensemble heterogeneity, whilst allowing simultaneous measurement of 37 
 
3 
oligomer ζ-potential, a hitherto inaccessible parameter. In addition, the short experimental 1 
timescale (analysis time ~ 5 s), solution-phase conditions and minimal sample dilution enable 2 
an accurate, native-state snapshot of dynamic oligomer populations with high temporal 3 
resolution.  4 
First, we demonstrate the principle of our method through analysis of stable, fluorophore-5 
labelled kinetically trapped αS oligomers that have been characterised in detail previously,11 6 
before applying the technique to the analysis of transient oligomers that arise during protein 7 
aggregation. Moreover, by use of an oligomer-selective aptamer probe, we further 8 
demonstrate the broad applicability of our method by investigation of wild-type, unlabelled αS 9 
oligomers.  10 
Results and Discussion  11 
Our microchip electrophoretic approach is based on a μFFE16,17 platform18 that allows rapid 12 
fractionation of samples containing a complex mixture of oligomeric and monomeric proteins 13 
(Figure 1(a)). The sample, flanked by an auxiliary buffer, is passed under laminar flow through 14 
the microfluidic chip whilst an electric field is applied perpendicular to the flow direction, 15 
resulting in fractionation of the heterogeneous mixture according to the different 16 
electrophoretic mobilities of the sample components (Figure 1(b)). Notably, our device 17 
incorporates an in-line microfluidic sample-desalting19,20 module for rapid ( ~ 2 s) sample 18 
preparation on chip (Figure S1, Supporting Information). This enables the use of high-salt, 19 
physiologically-relevant buffers such as phosphate buffered saline (PBS), which are otherwise 20 
inaccessible in μFFE, as excessive ionic conduction through the buffer prevents the 21 
application of electric field. To allow facile in-situ differentiation between monomeric and 22 
oligomeric αS fractions (Figure 1(b)), αS monomer labelled with a fluorophore (Alexa546) 23 
orthogonal to that of the oligomeric protein mixture (Alexa488) is introduced as an in-situ 24 
reference. For this approach to be effective, it is necessary for both αS labelling variants to 25 
possess the same electrophoretic mobility; hence, the dyes were chosen due to their same 26 
inherent charge,21 and quantification of the mobilities of the two labelling variants confirmed 27 
that they were identical, with μ =  − 1.43 ± 0.11 × 10 − 8 m2 V  − 1 s  − 1 (Figure S2). Moreover, 28 
comparative analysis of fluorophore-labelled and wild-type αS oligomers by circular dichroism, 29 
Fourier transform infra-red spectroscopy and transmission electron microscopy indicated 30 
almost identical structural characteristics between the oligomer variants (Figure S4, 31 
Supporting Information).  32 
We initially demonstrate separation of αS monomers from kinetically-trapped, stable αS 33 
oligomers prepared both in high and low-salt conditions (Figure 1(c)). Mixtures of kinetically 34 
stable, Alexa488-labelled oligomers together with both Alexa488 and 546-labelled monomer 35 
in PBS or 10 mM sodium phosphate buffer were analysed. Two distinct fractions were 36 
 
4 
observed for the oligomeric mixture (Alexa488), but only a single fraction was present for the 1 
monomer-only sample (Alexa546). By comparison to the Alexa546 fluorescence profile, the 2 
lower and higher mobility fractions could be clearly identified as monomeric and oligomeric 3 
protein, respectively (Figure 1↓(d, e)). As expected, a broad peak width is observed for 4 
monomer, resulting from faster diffusion due to its smaller hydrodynamic radius in comparison 5 
to oligomeric species. Indeed, further analysis revealed significant oligomer heterogeneity, 6 
with a similar electrophoretic profile for both conditions comprising a major oligomer population 7 
at μ = −2.49 ± 0.16 × 10 − 8 m2 V  − 1 s  − 1 combined with a significant high-mobility shoulder 8 
composed of smaller sub-populations.  9 
 10 
We attribute the electrophoretic separation of oligomer and monomer to the faster scaling of 11 
effective oligomer charge relative to oligomer size, for an oligomer of nm monomer units. 12 
Oligomer electrophoretic mobility (μo) is proportional to oligomer charge (qo) and inversely 13 







 , where 𝜈 is a 14 
scaling exponent that links 𝑞𝑜 with 𝑛𝑚. αS oligomers have been reported to possess an 15 







3   where 𝑉𝑜 , 16 
𝑉𝑚, 𝑟𝑜 and 𝑟𝑚 represent the oligomer and monomer volumes and oligomer and monomer 17 
hydrodynamic radii, respectively. Together, these expressions yield the oligomer 18 




According to this relationship, oligomers are expected to have higher mobilities than 20 
monomeric protein, and oligomer mobility is predicted to increase with oligomer size. 21 
Additional data, definition of apparent mobility and further discussion of desalting-μFFE are 22 









           (1) 24 
To verify this size–mobility relationship, we compared μFFE to AUC, which is an established 25 
technique for the analysis of size distributions within complex samples. A similar oligomer 26 
profile was consistently observed in both the AUC and μFFE analyses, indicating a scaling of 27 
oligomer electrophoretic mobility with oligomer size (Figure 1(f), additional data and 28 
rationalisation are provided in the SI). This observation shows that the electropherograms 29 
generated through μFFE correspond directly to size distributions of component species, as 30 
predicted by Equation 1, thus validating the μFFE approach as a tool for the analysis of 31 
oligomer structural heterogeneity. From the AUC analysis, values of ro were found to be in the 32 
range 5.8-11 nm, in agreement with those determined previously.11  33 
 
5 
Having shown that our μFFE approach enables the fractionation of oligomeric protein 1 
mixtures, we analysed the resultant oligomer electropherograms to access oligomer ζ-2 
potentials, a fundamental parameter of nanoscale aggregates. The ζ-potential describes 3 
interactions between particles, where it modulates the propensity of the system to aggregate 4 
further, and between aggregates and other biological components such as cell membranes. 5 
Previously, this parameter has been challenging to study for oligomeric protein aggregates, 6 
due to the high degree of structural heterogeneity intrinsic in oligomer samples that confounds 7 
conventional techniques, such as dynamic light scattering, for ζ-potential analysis.24 Since our 8 
method allows direct observation of oligomer heterogeneity during free-solution 9 
electrophoresis, ζ-potentials can be accurately assigned to the major oligomer population 10 
rather than to the population average. Following normalisation, the monomer-only Alexa546 11 
profile was subtracted from the Alexa488 signal to yield an electropherogram corresponding 12 
to oligomeric species only, and values for oligomer ζ-potential were extracted from the 13 
reported electrophoretic mobilities (Figure 1(e), see SI).25 The most common oligomer ζ-14 
potential of ζ = −42.6 ± 4.1 mV is characteristic of particulate systems with high colloidal 15 
stability.26,27 This finding is significant as it supports the view of protein oligomers as species 16 
that do not undergo aggregation themselves.28  The stability we observe suggests that these 17 
oligomers will not be removed from solution by flocculation or aggregation, consistent with 18 
them existing as a kinetically-trapped,11 long-lived colloidal suspension, with implications for 19 





Figure 1 (a) Schematic of device design for desalting-μFFE. The device operates through liquid KCl 2 
electrodes, allowing voltage application downstream of the electrophoresis chamber to prevent 3 
disruption of flow by electrolysis products.18 Reference sample can be introduced on-chip in pure water 4 
diluent, enabling rapid in-situ sample desalting prior to downstream electrophoresis. (b) Schematic for 5 
two-colour microfluidic free-flow electrophoresis of oligomeric αS. (c) Fluorescence images of 6 
Alexa546-labelled αS monomer reference and Alexa488-labelled oligomeric mixture undergoing μFFE 7 
in 10 mM sodium phosphate (NaPi) buffer (pH 7.4). Direction of fluid flow and electric field (E) shown 8 
by arrows, scale bar = 300 μm. (d) Electropherograms for Alexa546 monomer reference and Alexa488-9 
labelled αS oligomeric mixture fluorescence in PBS buffer. (e) Electropherograms for αS monomer and 10 
oligomeric mixture in 10 mM NaPi buffer. (f) AUC data for the same oligomer sample for data shown in 11 
(e), the peak at S ≈ 2 is due to monomeric protein. (g) Distribution of oligomer ζ-potential.  12 
 13 
Notably, despite the relationship between surface charge and colloidal stability being of clear 14 
relevance to oligomer behaviour, few experimental studies have attempted to quantify ζ-15 
potential within heterogeneous oligomer populations, likely due to the challenges such an 16 
experiment would present for established techniques.30 The μFFE method offers a facile 17 
method for quantifying this parameter in protein aggregation systems, introducing an important 18 
parameter for understanding the physical-chemical nature of aggregate species.   19 
Following our analysis of kinetically-trapped, stable oligomers, we applied our μFFE platform 20 
to the study of transient αS oligomers formed during protein aggregation. Aliquots were 21 
 
7 
periodically withdrawn from the shaking-initiated aggregation reaction of Alexa488-labelled αS 1 
monomer, fibrillar components were removed by centrifugation before the samples were 2 
analysed by μFFE. High-mobility fractions in the aggregation mixture corresponding to 3 
oligomeric αS could be identified and quantified (Figure 2(a, b, c)), following comparison of 4 
the electrophoresis profiles for the aggregation mixture and the Alexa546-labelled monomer 5 
reference, which yielded electropherograms corresponding to oligomeric αS alone (Figure 6 
2(d)).  7 
No oligomers were observed prior to aggregation initiation, before their concentration 8 
increased through the lag phase of the reaction, reaching a peak concentration of 1.75 μM 9 
(monomer equivalent) out of a total αS concentration of 100 μM with concomitant initiation of 10 
protein fibrillisation after 36h. This behaviour is in good agreement with studies employing 11 
single-molecule Förster resonance energy transfer (smFRET) experiments.31 Furthermore, 12 
two distinct oligomeric subpopulations are observable in the aggregation time course, which 13 
corresponds well with smFRET experiments where two major subpopulations of αS oligomers 14 
have been observed.8,9 Oligomers with low FRET efficiency formed first in the aggregation 15 
reaction, before converting to species with high FRET efficiency, suggesting a more densely 16 
packed structure. Our finding that low mobility species evolve to form high mobility species is 17 
thus consistent with an increase in packing efficiency, corresponding to a decrease in 18 
hydrodynamic radius. 19 
However, smFRET techniques require up to 105-fold sample dilution, which may result in 20 
under-sampling of transient, weakly-bound oligomer species that are prone to dissociation.12,32 21 
In contrast, sample dilution is not required for μFFE, enabling accurate oligomer quantitation 22 
as evidenced by close agreement with values obtained by other techniques such as size 23 
exclusion chromatography.33 Notably, the μFFE experiment (≈ 5 s analysis time) is three 24 
orders of magnitude faster than methods such as AUC. This crucial feature allowed access to 25 
transient species that would be otherwise challenging to observe by AUC or other bulk 26 
separation methods, with minimal sample consumption of only a few μL.  27 
In addition to these approaches, previous studies have employed micro-capillary 28 
electrophoresis (MCE) techniques34,35 to analyse protein aggregation products; these works 29 
were primarily focused on the observation of fibrillar species rather than oligomers36 or were 30 
non-quantitative.37,38 While MCE techniques generally provide advantages in terms of 31 
resolution relative to μFFE,39,40 they pose challenges in the quantitation of rare species, due 32 
to the injection of a finite volume of sample. In contrast, the steady-state, continuous 33 
fractionation process intrinsic to μFFE prevents sample bleaching during data acquisition and 34 
enhances sensitivity through the use of arbitrary exposure time in conventional 35 
epifluorescence microscopy. These advantages over MCE techniques are key to our 36 
 
8 
application of μFFE to detecting and characterising lowly populated oligomeric species in 1 
aggregation reactions.  2 
 3 
 4 
Figure 2 (a) Fluorescence images of μFFE experiment of transient oligomers formed after 24 h αS 5 
aggregation. Scale bar = 300 μm. (b) Superimposed electropherograms of normalised alexa-488 and 6 
546 fluorescence for micrographs shown in (a), (inset) magnification of electropherograms showing 7 
oligomeric region. (c) Scatter plot showing progression of oligomer concentration (monomer 8 
equivalents) and extent of monomer to fibril conversion (fibril concentration in monomer equivalents) 9 
over the sampled time points. Error bars correspond to standard deviation of three repeat 10 
measurements of the same sample. (d) Electropherograms and smoothed traces corresponding to 11 
oligomeric species only at each sampled aggregation time point.  12 
 13 
Further to the fluorophore-tagged protein systems discussed so far, μFFE can be employed 14 
for the analysis of wild-type oligomeric species when used in conjunction with an appropriate 15 
oligomer-binding probe. We demonstrate this capability by utilising a fluorophore-tagged 16 
aptamer selective for αS oligomers.41 As shown previously,42 protein–aptamer binding retards 17 
the electrophoretic mobility of the aptamer, enabling separation of the bound and unbound 18 
fractions (Figure 3(a)). Aliquots taken from stirring-induced aggregation of wild-type αS were 19 
 
9 
incubated with the aptamer and analysed by μFFE (Figure 3(b)). After 4.25 h aggregation time, 1 
an additional fraction at lower mobility than the unbound aptamer was observed. By peak 2 
integration and assuming 1:1 binding stoichiometry, an upper bound of 80 nM oligomer 3 
concentration could be estimated (Figure 3(c)). By comparison to the maximal monomer-4 
equivalent concentration of labelled oligomer observed previously (Figure 2(c)), it could be 5 
approximated that around twenty monomer units are present in each oligomer, in good 6 
agreement with previously ascertained values.11 The oligomeric nature of the peak was 7 
confirmed by μFFE of the aptamer in the presence of αS monomer alone and sonicated αS 8 
fibrils (Supporting Information). These data show that label-free, wild-type oligomers can be 9 
observed and quantified by μFFE, and demonstrates the versatility of our method towards 10 
applications involving immunochemistry-based oligomer detection and manipulation.  11 
 12 
 13 
Figure 3 (a) Schematic for fractionation of oligomer-bound and unbound aptamer by μFFE. (b) Images 14 
of aptamer fluorescence during μFFE, from aptamer mixed into an aggregation reaction of wild-type αS 15 
at 0 h and 4.25 h timepoints. Additional, lower-mobility fraction after 4.25 h indicates aptamer-oligomer 16 
binding. (c) Analysis and integration of aptamer electropherograms enable approximation of the 17 
concentration of aptamer-bound oligomers.  18 
 19 
Conclusion  20 
Oligomeric proteins are heavily implicated as toxic agents in protein-misfolding diseases. 21 
Understanding oligomer structure, heterogeneity, and physical properties in solution 22 
conditions is of vital importance to elucidate relationships between oligomer structure and 23 
toxicity, and to enable the design of effective therapeutics. 24 
The μFFE platform presented here is a multifaceted tool for the observation and analysis of 25 
these pre-fibrillar intermediates in free solution and physiological conditions. Using this 26 
approach, we demonstrate characterisation of oligomer structural heterogeneity within 27 
populations of both kinetically-stabilised and transient, on-pathway oligomers isolated from 28 
 
10 
aggregation reaction mixtures. Crucially, on-chip sample preparation and the rapid 1 
experimental timescale enabled by the μFFE platform results in minimal sample perturbation 2 
and very high temporal resolution. We quantify oligomer zeta-potential, with our results 3 
indicating a high degree of oligomer colloidal stability, supporting the view that oligomers are 4 
relatively long-lived species with a low propensity to directly aggregate themselves. 5 
Significantly, we observe an interaction between wild-type oligomers and an immuno-probe in 6 
free solution. These properties are fundamental to both the physical and biological 7 
understanding of oligomer behaviour, but are challenging to study using conventional methods 8 
due to the intrinsic heterogeneity of oligomer samples. 9 
Oligomer μFFE has many potential applications, such as in the analysis of protein aggregation 10 
kinetics, the links between oligomer structure and toxicity, and for screening protein–protein 11 
and protein–small molecule interactions in the development of therapeutic interventions for 12 
misfolding disease. More broadly, our findings demonstrate the suitability of free-flow 13 
electrophoretic methods for the quantitative, free-solution analysis of nanoparticle analytes in 14 
general, according to their size and surface properties.  15 
Supporting Information  16 
Additional methods, detail concerning the microfluidic device, control experiment data, 17 
additional experimental data, theoretical basis for this work, and oligonucleotide sequences 18 
are provided in the Supporting Information. 19 
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